SCHEMBL5656080

SCHEMBL5656080

O=C(c1ccc(I)cc1)c1ccc(NC(=O)C(Cl)(Cl)Cl)c(C(=O)c2cccc(Cl)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.50
SERPINE1 P05121 1/20 0.47
ALDH1A1 P00352 5/20 0.46
LMNA P02545 3/20 0.46
TP53 P04637 2/20 0.45
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PDK1 Q15118 2/20 0.41
PDK2 Q15119 2/20 0.41
PDK3 Q15120 2/20 0.41
PDK4 Q16654 2/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3555488 0.89 MAPT (0.48) MAPTSERPINE1ALDH1A1LMNATP53
SCHEMBL3555862 0.88 TP53 (0.50) MAPTSERPINE1ALDH1A1LMNATP53
SCHEMBL3552210 0.85 ALDH1A1 (0.54) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL5023776 0.82 ALDH1A1 (0.59) MAPTALDH1A1LMNATP53GAA
SCHEMBL5655125 0.81 RAB9A (0.52) MAPTALDH1A1TP53SMN1; SMN2HPGD
SCHEMBL5023284 0.81 PRSS12 (0.43) MAPTSERPINE1ALDH1A1LMNATP53
SCHEMBL8569299 0.80 MAPT (0.67) MAPTSERPINE1ALDH1A1LMNATP53
SCHEMBL5545688 0.80 DOT1L (0.51) MAPTSERPINE1ALDH1A1GAASMN1; SMN2
SCHEMBL3025938 0.79 PARP1 (0.53) SERPINE1ALDH1A1
SCHEMBL5782330 0.77 MAPT (0.55) MAPTSERPINE1ALDH1A1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173040-B2 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-06 US disclosed
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties JANSSEN-CILAG S.A. (FR) 2004-03-11 US disclosed
EP-1322636-A1 FARNESYL TRANSFERASE INHIBITING 6- (SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024683-A1 FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties FNTB, FNTA, CYP7A1 MAPT 3556/4885SERPINE1 1216/4885ALDH1A1 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.